spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Signant Health Unveils its full Conference Line-up for SCOPE 2020

Signant Health

Subject matter experts, technologists, scientists and executives to advance patient-centric conversations with innovative clinical operations leaders from global pharmaceutical companies

PHILADELPHIA, PA – February 11, 2020: The SCOPE Summit for Clinical Operations Executives annually convenes innovative thought leaders from across the life sciences industry to share ideas, challenges and best practices that will help drive change and improve patient centricity throughout the coming year and beyond. Subject matter experts from Signant Health will host and participate in key discussions on the importance of eConsent and patient engagement, the impact of data analytics on endpoint quality, and how to integrate sensors and wearables into eCOA trials as part of the patient journey through clinical research.

Join the conversation at SCOPE with these engaging sessions:

Keynote Panel - Taking the Plunge: Why Now is the Time to Invest in eConsent and Patient Engagement
Moderated by Bill Byrom, MD | VP, Product Strategy and Innovation Featuring panellists Michelle Shogren (Bayer Pharmaceuticals), Hassan Kadhim (Bristol Myers-Squibb), Kelly McKee (Vertex Pharmaceuticals) and Gretchen Goller (ICON plc)
Tuesday, February 18 at 5:05pm

Mobile Sensors in Clinical Trials and Evidentiary Considerations for Electronic Submissions
Presented by Dr. Byrom
Wednesday, February 19 at 10:55am

Using Advanced Risk-Based Monitoring Models to Improve Endpoint Quality
Presented by Todd Everhart, MD | Clinical Vice President, Internal Medicine
Wednesday, February 19 at 12:50pm

Navigating the Patient Journey: A Responsibility All Technology Providers Share
Presented by Mike Nolte | CEO
Thursday, February 20 at 7:45am

Novel Digital Endpoints in Clinical Research: Technology, Infrastructure, Relationship with Technology Providers
Moderated by Michelle Crouthamel (AbbVie)
Featuring panellists Mike Nolte, Jeremy Wyatt (Actigraph), Jennifer Goldsack (DiMe) and Sina Djali (Johnson & Johnson)
Thursday, February 20 at 11:45am

Enable Empowered Patients in Clinical Trials by Integrating the Patient’s Voice, Health Literacy and Cultural Sensitivity
Sessions chaired by Chris Crucitti | Chief Commercial Officer
Thursday, February 20 at 4:10pm

Visitors to the Signant Health exhibit booth will have the opportunity to meet with subject matter experts, technologists and scientists and go hands-on with the latest patient-centric technologies including eCOA, sensors and wearables, eConsent, patient engagement, IRT and more.

Mike Nolte, CEO of Signant Health said, “Many of our partners and colleagues see opportunities to transform clinical research through the eyes of the patient. For us, this is deeply personal, and the beauty of SCOPE is that it brings together all of the people who are in the position – and who have the passion – to make that change a reality. SCOPE is a unique gathering because it links great leaders to great thinking that spans the tactical and strategic. We are proud to get the opportunity to collaborate and share with partners and colleagues across so many critical themes and challenges within clinical research."

To learn more about Signant Health visit https://signanthealth.com/.

Who Is Signant Health?

The best technology succeeds in the background. Signant Health (formerly CRF Health and Bracket) provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at signanthealth.com.

CRF Health and Bracket are now Signant Health.

Contact: media@signanthealth.com, +1 267.498.2350




phone +1 267 498 2300
email media@signanthealth.com
web https://signanthealth.com/
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>


White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement